All In Biotech

Drug Trial Radar · NCT06082037

A Study to Test How Effective Belumosudil Tablets Are for Treating Adult Participants With Chronic Lung Allograft Dysfunction

A Randomized, Double-blind, Placebo-controlled, Parallel Group, Phase 3 Study, Followed by Open-label Extensions, to Evaluate the Efficacy of Oral Belumosudil in Adult Participants With Chronic Lung Allograft Dysfunction (CLAD) Following Bilateral Lung Transplantation

Last checked: Nov 20, 2026Latest source record: Oct 28, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 180 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

180

Planned (sponsor's estimate)

Start

Oct 10, 2023

Primary completion

Jan 29, 2029

Study completion Oct 1, 2030

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
Collaborators
Meiji Seika Pharma Co., Ltd.
First posted
Oct 13, 2023

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This double-blind, randomized, placebo-controlled, multinational, multicenter, parallel-group, Phase 3, 2-arm, study will investigate the efficacy and safety of belumosudil compared with placebo, both administered on top of azithromycin and standard-of-care regimen of immunosuppression in male or female participants at least 1 year after bilateral lung transplant, who are at least 18 years of age and who have evidence of progressive CLAD despite azithromycin therapy. Study details include: The study duration will be up to 31 weeks for participants not entering the open-label extension (OLE) period and up to 57 weeks for participants entering the OLE period but not the long-term OLE. The treatment duration will be up to 26 weeks for participants not entering the OLE period and up to 52 weeks for participants entering the OLE period but not the long-term OLE. The number of visits will be up to 10 visits for participants not entering the OLE period and up to 16 visits for participants entering the OLE period but not the long-term OLE. For participants who enter the long-term OLE, treatment and study participation will continue with visits every 12 weeks per protocol specifications.

Conditions

  • Lung Transplant Rejection

Interventions

  • BelumosudilDrug

    Tablet, Oral

  • AzithromycinDrug

    Depends on pharmaceutical presentation, Oral

  • PlaceboDrug

    Tablet, Oral

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Percent change from baseline to Week 26 in forced expiratory volume in 1 second (FEV1)Time frame: Baseline to Week 26

Locations

85 sites in 20 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham- Site Number : 8400026

    Birmingham, Alabama · Recruiting

  • St. Joseph's Hospital and Medical Center- Site Number : 8400019

    Phoenix, Arizona · Recruiting

  • University of California Los Angeles Medical Center- Site Number : 8400020

    Los Angeles, California · Recruiting

  • Stanford University Medical Center- Site Number : 8400008

    Stanford, California · Recruiting

  • Mayo Clinic in Florida- Site Number : 8400031

    Jacksonville, Florida · Recruiting

  • Jackson Memorial Hospital- Site Number : 8400030

    Miami, Florida · Recruiting

  • AdventHealth Orlando- Site Number : 8400023

    Orlando, Florida · Completed

  • Tampa General Hospital - Tampa - General Circle- Site Number : 8400015

    Tampa, Florida · Recruiting

  • Emory University Hospital- Site Number : 8400027

    Atlanta, Georgia · Recruiting

  • Northwestern University- Site Number : 8400003

    Chicago, Illinois · Recruiting

  • Loyola University Medical Center- Site Number : 8400025

    Maywood, Illinois · Recruiting

  • University of Iowa- Site Number : 8400032

    Iowa City, Iowa · Recruiting

  • University of Maryland School of Medicine - Baltimore- Site Number : 8400009

    Baltimore, Maryland · Recruiting

  • Johns Hopkins Hospital- Site Number : 8400034

    Baltimore, Maryland · Recruiting

  • Brigham & Women's Hospital- Site Number : 8400016

    Boston, Massachusetts · Completed

  • University of Michigan Health System - Ann Arbor- Site Number : 8400014

    Ann Arbor, Michigan · Recruiting

  • Corewell Health - Grand Rapids - Michigan Street Northeast- Site Number : 8400010

    Grand Rapids, Michigan · Recruiting

  • Mayo Clinic in Rochester - Minnesota- Site Number : 8400038

    Rochester, Minnesota · Recruiting

  • NYU Perlmutter Cancer Center - Energy Building- Site Number : 8400001

    New York, New York · Recruiting

  • Icahn School of Medicine at Mount Sinai- Site Number : 8400037

    New York, New York · Recruiting

  • Columbia University Irving Medical Center- Site Number : 8400002

    New York, New York · Recruiting

  • Montefiore Medical Center - Moses Campus- Site Number : 8400036

    The Bronx, New York · Recruiting

  • Duke University Medical Center- Site Number : 8400017

    Durham, North Carolina · Recruiting

  • Cleveland Clinic - Cleveland- Site Number : 8400005

    Cleveland, Ohio · Recruiting

  • The Ohio State University- Site Number : 8400028

    Columbus, Ohio · Recruiting

  • Penn Medicine: University of Pennsylvania Health System- Site Number : 8400006

    Philadelphia, Pennsylvania · Recruiting

  • Temple University Hospital- Site Number : 8400007

    Philadelphia, Pennsylvania · Recruiting

  • Vanderbilt University Medical Center- Site Number : 8400018

    Nashville, Tennessee · Recruiting

  • Baylor University Medical Center- Site Number : 8400011

    Dallas, Texas · Completed

  • University of Texas - Southwestern Medical Center- Site Number : 8400013

    Dallas, Texas · Recruiting

  • Baylor College of Medicine- Site Number : 8400024

    Houston, Texas · Recruiting

  • Houston Methodist Hospital- Site Number : 8400021

    Houston, Texas · Recruiting

  • University Health System - San Antonio- Site Number : 8400035

    San Antonio, Texas · Recruiting

  • University of Utah Medical Group- Site Number : 8400039

    Salt Lake City, Utah · Recruiting

  • Inova Fairfax Hospital- Site Number : 8400004

    Falls Church, Virginia · Recruiting

  • Investigational Site Number : 0360003

    Darlinghurst, New South Wales, Australia · Recruiting

  • Investigational Site Number : 0360001

    Brisbane, Queensland, Australia · Recruiting

  • Investigational Site Number : 0360002

    Murdoch, Western Australia, Australia · Recruiting

  • Investigational Site Number : 0400001

    Vienna, Austria · Recruiting

  • Investigational Site Number : 0560001

    Leuven, Belgium · Recruiting

Showing 40 of 85 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.